Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Farmers Insurance
UBS
Teva
Mallinckrodt
Federal Trade Commission

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,913,768

« Back to Dashboard

Summary for Patent: 6,913,768
Title: Sustained release delivery of amphetamine salts
Abstract:A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR.RTM. type pulsatile formulations.
Inventor(s): Couch; Richard A. (Bryn Mawr, PA), Burnside; Beth A. (Bethesda, MD), Chang; Rong-Kun (Rockville, MD)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:10/353,073
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,913,768
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,913,768
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 6,913,768

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shire Dev Llc MYDAYIS amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 022063-001 Jun 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER ➤ Sign Up
Shire Dev Llc MYDAYIS amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 022063-002 Jun 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER ➤ Sign Up
Shire Dev Llc MYDAYIS amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 022063-003 Jun 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER ➤ Sign Up
Shire Dev Llc MYDAYIS amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 022063-004 Jun 20, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
McKinsey
AstraZeneca
Chubb
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.